CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr | ₹17,132 Cr |
What is the latest Revenue of CIPLA ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹25,774 Cr |
| Mar2024 | ₹22,753 Cr |
| Mar2023 | ₹21,763 Cr |
| Mar2022 | ₹19,160 Cr |
| Mar2021 | ₹17,132 Cr |
How is Revenue of CIPLA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹25,774 Cr | 13.28 | |
| Mar2024 | ₹22,753 Cr | 4.55 | |
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | 11.84 | |
| Mar2021 | ₹17,132 Cr | - | |
Compare Revenue of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹96,402.9 Cr | -4.1% | -11.5% | -19% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,603.0 Cr | -5.6% | -2.5% | -1.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹155,485.0 Cr | -2.6% | -8.7% | 1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹135,009.0 Cr | -7.2% | -8% | 27.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,628.0 Cr | -6.5% | -5.4% | 3.9% | Stock Analytics | |
| MANKIND PHARMA | ₹82,460.4 Cr | -1.1% | -11.1% | -16.9% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -4.1% |
-11.5% |
-19% |
| SENSEX | -1% |
-10.9% |
-6% |
You may also like the below Video Courses